159938 医药
已收盘 05-26 15:00:00
资讯
新帖
简况
同仁堂最新公告:控股子公司终止对红惠医药投资并退出
证券之星 · 17:21
同仁堂最新公告:控股子公司终止对红惠医药投资并退出
创胜集团医药-B(06628)公布收到HiCB对外授权里程碑付款及CDMO业务稳步增长
智通财经 · 16:35
创胜集团医药-B(06628)公布收到HiCB对外授权里程碑付款及CDMO业务稳步增长
英硅智能与奕拓医药深化战略合作
南方财经网 · 08:51
英硅智能与奕拓医药深化战略合作
毛利率“贴地飞行”、净利“坐过山车”,融泰药业叩门港股,院外医药服务商“两头受气”隐忧待解
蓝鲸财经 · 05-25 21:42
毛利率“贴地飞行”、净利“坐过山车”,融泰药业叩门港股,院外医药服务商“两头受气”隐忧待解
三展联合举办 助推医药全产业链提质增效
国药集团 · 05-25 19:13
三展联合举办 助推医药全产业链提质增效
何氏眼科:5月25日接受机构调研,招商医药、圆信永丰基金等多家机构参与
证券之星 · 05-25 19:01
何氏眼科:5月25日接受机构调研,招商医药、圆信永丰基金等多家机构参与
欧康医药(920230)披露投资者关系活动记录表,5月25日股价下跌1.08%
证券之星 · 05-25 18:26
欧康医药(920230)披露投资者关系活动记录表,5月25日股价下跌1.08%
5月25日司太立跌7.04%,银河医药混合A基金重仓该股
证券之星 · 05-25 16:32
5月25日司太立跌7.04%,银河医药混合A基金重仓该股
新股消息 | 融泰药业二次递表港交所 为中国院外医药市场第三大数字化营销和供应链服务提供商
智通财经 · 05-23
新股消息 | 融泰药业二次递表港交所 为中国院外医药市场第三大数字化营销和供应链服务提供商
新股消息 | 勤浩医药拟港股上市 中国证监会要求补充说明近三年净资产数据等事项
智通财经 · 05-22
新股消息 | 勤浩医药拟港股上市 中国证监会要求补充说明近三年净资产数据等事项
复宏汉霖(02696):斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见
智通财经 · 05-22
复宏汉霖(02696):斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见
森萱医药(920946)披露关于注销募集资金专户的公告,5月22日股价下跌0.52%
证券之星 · 05-22
森萱医药(920946)披露关于注销募集资金专户的公告,5月22日股价下跌0.52%
白云山(00874):广州医药完成10亿元应收账款资产证券化
智通财经 · 05-22
白云山(00874):广州医药完成10亿元应收账款资产证券化
青海湟中全域推广中(藏)医药康养文化 让传统医药可触可享
中国新闻网 · 05-21
青海湟中全域推广中(藏)医药康养文化 让传统医药可触可享
5月21日司太立跌6.25%,银河医药混合A基金重仓该股
证券之星 · 05-21
5月21日司太立跌6.25%,银河医药混合A基金重仓该股
创新药迎政策利好 富国港股通医药优选即将结束募集
新浪基金 · 05-21
创新药迎政策利好 富国港股通医药优选即将结束募集
创胜集团医药-B(06628)合作伙伴INHIBRX报告OZEKIBART的CRC最新积极数据并宣布就治疗软骨肉瘤提交美国BLA申请
智通财经 · 05-21
创胜集团医药-B(06628)合作伙伴INHIBRX报告OZEKIBART的CRC最新积极数据并宣布就治疗软骨肉瘤提交美国BLA申请
森萱医药(920946)披露2025年年度权益分派实施公告,5月20日股价下跌1.87%
证券之星 · 05-20
森萱医药(920946)披露2025年年度权益分派实施公告,5月20日股价下跌1.87%
脑机接口尚处早期 AD药效待突破!下一个医药爆款在何处?
21世纪经济报道 · 05-20
脑机接口尚处早期 AD药效待突破!下一个医药爆款在何处?
5月20日热景生物跌9.64%,富国医药创新股票A基金重仓该股
证券之星 · 05-20
5月20日热景生物跌9.64%,富国医药创新股票A基金重仓该股
暂无数据
公司概况
公司名称:
--
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.602,"timestamp":1779779031000,"preClose":0.603,"halted":0,"volume":48445402,"delay":0,"changeRate":-0.0017,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.001,"latestTime":"05-26 15:00:00","open":0.602,"high":0.604,"low":0.597,"amount":29067500,"amplitude":0.0116,"askPrice":0.602,"askSize":2790,"bidPrice":0.601,"bidSize":8589,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.603,"symbolType":"fund","openAndCloseTimeList":[[1779759000000,1779766200000],[1779771600000,1779778800000]],"highLimit":0.663,"lowLimit":0.543,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.232293,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938/tweets","defaultTab":"tweets","newsList":[{"id":"2638590675","title":"同仁堂最新公告:控股子公司终止对红惠医药投资并退出","url":"https://stock-news.laohu8.com/highlight/detail?id=2638590675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638590675?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:21","pubTimestamp":1779787299,"startTime":"0","endTime":"0","summary":"同仁堂(600085.SH)公告称,公司控股子公司同仁堂商业终止对红惠医药51%股权的收购,并以定向减资方式退出。同时,控股股东同仁堂集团以委托贷款方式向同仁堂商业拨付1000万元国有资本经营预算资金,贷款期限三年。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600029133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0086","LU1688375341.USD","BK0113","600085","BK0196","BK0097","BK0012","BK1161","BK1574","BK1515","BK0239","BK0188","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638659263","title":"创胜集团医药-B(06628)公布收到HiCB对外授权里程碑付款及CDMO业务稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2638659263","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638659263?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:35","pubTimestamp":1779784520,"startTime":"0","endTime":"0","summary":"智通财经APP讯,创胜集团医药-B 发布公告,公司已收到来自其HiCB平台对外授权的一笔里程碑付款人民币700万元,同时其CDMO业务亦取得重大进展。迄今为止,创胜集团已成功完成关键可交付条件。同时,创胜集团的CDMO业务亦取得稳步进展。随着HiCB对外授权项目取得进展以及CDMO业务持续扩张,创胜集团依然处于有利位置,以推动可持续增长并为其合作伙伴及股东创造长期价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09939","CDMO","159938","BK1515","06628","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638661205","title":"英硅智能与奕拓医药深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2638661205","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638661205?lang=zh_cn&edition=full","pubTime":"2026-05-26 08:51","pubTimestamp":1779756660,"startTime":"0","endTime":"0","summary":"【英硅智能与奕拓医药深化战略合作】据英硅智能消息,英硅智能与无锡奕拓医药科技有限责任公司签署扩大战略合作协议。双方将在已有针对肿瘤靶点的蛋白降解小分子候选药物研发合作阶段性交付的基础上,进一步拓展合作适应症,聚焦AI赋能皮肤管理与皮肤抗衰老领域创新药物开发。依托人工智能驱动的生物学平台与LLPS特色研发平台,推动用于科学护肤及皮肤抗衰老的原创小分子药物从基础研究加速迈向临床应用与产业落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605263748832427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1161","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638553263","title":"毛利率“贴地飞行”、净利“坐过山车”,融泰药业叩门港股,院外医药服务商“两头受气”隐忧待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2638553263","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638553263?lang=zh_cn&edition=full","pubTime":"2026-05-25 21:42","pubTimestamp":1779716524,"startTime":"0","endTime":"0","summary":"融泰药业是国内主要的院外药品市场数字化营销和供应链服务提供商,主要从事在线、线下药品零售及批发业务。融泰药业对上游制药公司及授权经销商存在较明显依赖。不可否认,处方外流、“双通道”药店、慢病管理需求增长,推动中国院外医药市场规模预计2030年突破万亿,数字化营销及供应链服务市场同期有望达4321亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779716139691975906","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4588","09939","159938","BK4585","BK1161","BK1515","BK1574","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638530103","title":"三展联合举办 助推医药全产业链提质增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638530103","media":"国药集团","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638530103?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:13","pubTimestamp":1779707580,"startTime":"0","endTime":"0","summary":"展会深入贯彻落实健康中国国家战略部署,积极践行“以人民健康为中心”的发展理念,以全球视野引领医药产业创新,推动产业链融合驱动提质增效,为行业高质量发展注入新动能。创新驱动发展,构建全链条服务三展联合举办,贯通医药及健康营养产业全产业链,促进上下游高效协同与资源互通,联合打造首发产品系列活动,构建新品首发阵地,激发产品创新活力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-25/doc-inhzchzh3490720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159938","BK1161","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638353785","title":"何氏眼科:5月25日接受机构调研,招商医药、圆信永丰基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2638353785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638353785?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:01","pubTimestamp":1779706911,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年5月25日何氏眼科发布公告称公司于2026年5月25日接受机构调研,招商医药、圆信永丰基金、拾贝投资参与。何氏眼科2026年一季报显示,一季度公司主营收入3.05亿元,同比上升4.7%;归母净利润3268.88万元,同比上升0.48%;扣非净利润3081.18万元,同比下降1.21%;负债率13.94%,投资收益153.46万元,财务费用159.7万元,毛利率44.24%。以上内容为证券之星据公开信息整理,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","301103","BK1574","09939","BK0236","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534002","title":"欧康医药(920230)披露投资者关系活动记录表,5月25日股价下跌1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534002?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:26","pubTimestamp":1779704778,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,欧康医药报收于11.0元,较前一交易日下跌1.08%,最新总市值为11.08亿元。该股当日开盘11.17元,最高11.33元,最低10.84元,成交额达1243.98万元,换手率为2.38%。近日,欧康医药披露《投资者关系活动记录表》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638536561","title":"5月25日司太立跌7.04%,银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638536561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638536561?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:32","pubTimestamp":1779697942,"startTime":"0","endTime":"0","summary":"证券之星消息,5月25日司太立跌7.04%,收盘报11.75元,换手率13.87%,成交量60.79万手,成交额7.25亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为银河基金的银河医药混合A。方伟在任的基金产品包括:银河康乐股票A,管理时间为2021年5月10日至今,期间收益率为-25.03%;银河医药混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500022670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK0239","BK1515","BK1574","BK1161","603520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637881324","title":"新股消息 | 融泰药业二次递表港交所 为中国院外医药市场第三大数字化营销和供应链服务提供商","url":"https://stock-news.laohu8.com/highlight/detail?id=2637881324","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637881324?lang=zh_cn&edition=full","pubTime":"2026-05-23 17:27","pubTimestamp":1779528461,"startTime":"0","endTime":"0","summary":"根据弗若斯特沙利文的资料,按2025年收入计,融泰药业是中国院外医药市场第三大数字化营销和供应链服务提供商。融泰药业为上游制药公司对接最佳电商销售资源。融泰药业的宜康思大药房是将药品推向市场的额外渠道。行业概览招股书提到,受政府利好政策及用药需求不断增加的影响,中国院外医药市场规模于近年增长迅速,占医药市场总体规模的比例亦逐步增加。近年来,中国院外数字化营销及供应链服务市场规模快速增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","HEXmain","IPOS","159938","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310625","title":"新股消息 | 勤浩医药拟港股上市 中国证监会要求补充说明近三年净资产数据等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310625","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637310625?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:52","pubTimestamp":1779457966,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,5月22日,中国证监会公布境外发行上市备案补充材料要求公示。中国证监会国际司共对17家企业出具补充材料要求,其中,要求勤浩医药补充公司近三年净资产、净利润数据等事项。据悉,勤浩医药已于2026年1月16日递表港交所,华泰国际为独家保荐人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK4588","VXUS","BK1515","BK1161","BK4585","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317411","title":"复宏汉霖(02696):斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637317411?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:51","pubTimestamp":1779457861,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖 发布公告,近日,公司自主开发的斯鲁利单抗注射液获欧洲药品管理局人用医药产品委员会积极审评意见,推荐批准斯鲁利单抗联合卡铂和白蛋白紫杉醇适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。一旦获得EC批准,斯鲁利单抗的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于一项随机、双盲、国际多中心3期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","HK0000165453.HKD","HK0000320264.USD","02696","BK1574","HK0000306701.USD","09939","BK1161","BK1515","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138573","title":"森萱医药(920946)披露关于注销募集资金专户的公告,5月22日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138573?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:00","pubTimestamp":1779444054,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,森萱医药报收于9.64元,较前一交易日下跌0.52%,最新总市值为41.15亿元。该股当日开盘9.81元,最高9.81元,最低9.57元,成交额达1962.52万元,换手率为0.48%。近日,森萱医药发布《关于注销募集资金专户的公告》。相关《募集资金专户三方监管协议》随之终止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637909390","title":"白云山(00874):广州医药完成10亿元应收账款资产证券化","url":"https://stock-news.laohu8.com/highlight/detail?id=2637909390","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637909390?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:29","pubTimestamp":1779442189,"startTime":"0","endTime":"0","summary":"智通财经APP讯,白云山 发布公告,于2026年4月27日,广州医药与兴证资管签订《兴业圆融-广州医药应收账款5期资产支持专项计划基础资产买卖协议》,发行规模为人民币10亿元。据此,广州医药于2026年5月22日与兴证资管签订《交割确认函》,确认向兴证资管出售初始基础资产,并收到购买价款人民币10亿元。广州医药为本公司的一家于中国成立的非全资附属公司,由本公司拥有90.92%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0096","BK0183","BK1606","BK1161","600332","BK0012","BK1574","BK0239","BK0188","09939","BK0196","BK0028","BK1515","BK0097","BK1191","BK0175","BK1197","BK1521","00874","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637433604","title":"青海湟中全域推广中(藏)医药康养文化 让传统医药可触可享","url":"https://stock-news.laohu8.com/highlight/detail?id=2637433604","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637433604?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:42","pubTimestamp":1779367320,"startTime":"0","endTime":"0","summary":"中新网西宁5月21日电 5月21日,青海省西宁市湟中区首届中(藏)医药康养文化推广活动在湟中区中医院启幕,让传统医药文化可感、可触、可享。此前,《中华医藏·藏医药卷》成果发布会在北京举行。作为河湟文化核心发源地,湟中区中(藏)医药传承历史悠久、民众根基深厚。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-21/doc-inhyshrf6355481.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-21/doc-inhyshrf6355481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1161","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637383065","title":"5月21日司太立跌6.25%,银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637383065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637383065?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:28","pubTimestamp":1779352119,"startTime":"0","endTime":"0","summary":"证券之星消息,5月21日司太立跌6.25%,收盘报12.89元,换手率14.24%,成交量62.42万手,成交额8.31亿元。重仓司太立的公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为14.08。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.46亿元,最新净值0.5976,较上一交易日下跌0.83%,近一年上涨14.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","BK0239","603520","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806569","title":"创新药迎政策利好 富国港股通医药优选即将结束募集","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806569","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637806569?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:58","pubTimestamp":1779335880,"startTime":"0","endTime":"0","summary":"近期,中国创新药出海再添重磅利好,恒瑞医药与BMS达成总金额约152亿美元的全球战略合作,标志着国内创新药从“出海授权”迈入“全球共创”新周期;与此同时,港版FDA计划于年底成立,内地医保目录调整同步提速,创新药产业迎来多重利好。在此背景下,富国港股通医药优选混合型证券投资基金正在发行中,并将于5月22日结束募集。该基金专注港股医药赛道,为投资者布局港股创新药龙头提供便捷通道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-21/doc-inhyrrtp6358211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159938","BK1161","BK1574","159992","BK4588","09939","BK4585","06978","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637879691","title":"创胜集团医药-B(06628)合作伙伴INHIBRX报告OZEKIBART的CRC最新积极数据并宣布就治疗软骨肉瘤提交美国BLA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637879691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637879691?lang=zh_cn&edition=full","pubTime":"2026-05-21 06:25","pubTimestamp":1779315934,"startTime":"0","endTime":"0","summary":"智通财经APP讯,创胜集团医药-B 发布公告,其合作伙伴Inhibrx Biosciences, Inc. 近期报告了其评估ozekibart 联合FOLFIRI用于局部晚期或转移性、不可切除结直肠癌患者的1/2期研究的积极更新中期数据。除CRC适应症外,Inhibrx宣布ozekibart于软骨肉瘤方面取得一项重要监管里程碑。于2026年4月,Inhibrx已向FDA提交ozekibart用于常规软骨肉瘤的BLA,而该疾病目前尚无获批准的系统性治疗选项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4213","BK1161","LU0266512127.USD","09939","159938","06628","CRC","BK1515","LU0456854461.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636484566","title":"森萱医药(920946)披露2025年年度权益分派实施公告,5月20日股价下跌1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636484566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636484566?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:22","pubTimestamp":1779272539,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,森萱医药报收于9.95元,较前一交易日下跌1.87%,最新总市值为42.48亿元。该股当日开盘10.19元,最高10.22元,最低9.92元,成交额达2044.6万元,换手率为0.48%。森萱医药近日披露《2025年年度权益分派实施公告》。公告显示,公司2025年年度权益分派方案已获2026年5月18日股东会审议通过。本次权益分派以公司现有总股本426,918,340股为基数,向全体股东每10股派1.6元人民币现金,共计派发现金红利68,306,934.40元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636122758","title":"脑机接口尚处早期 AD药效待突破!下一个医药爆款在何处?","url":"https://stock-news.laohu8.com/highlight/detail?id=2636122758","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636122758?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:28","pubTimestamp":1779265680,"startTime":"0","endTime":"0","summary":"【脑机接口尚处早期 AD药效待突破!下一个医药爆款在何处?】2025年,A股医药板块上市公司交出的成绩单不可谓不亮眼。然而,与扎实的业绩基本面形成鲜明对比的,是相关公司股价的“温吞”表现。这一“叫好不叫座”的现象,成为近期产业与投资界热议的焦点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743503958.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743503958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","BK1574","09939","159938","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636581259","title":"5月20日热景生物跌9.64%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636581259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636581259?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:26","pubTimestamp":1779265601,"startTime":"0","endTime":"0","summary":"证券之星消息,5月20日热景生物跌9.64%创60日新低,收盘报83.85元,换手率4.92%,成交量4.57万手,成交额3.78亿元。重仓热景生物的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共24家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。该公募基金现任基金经理为赵伟 王超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000029434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688068","BK1574","09939","BK1161","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779801700907,"stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0822},{"period":"6month","weight":-0.108},{"period":"1year","weight":-0.0413},{"period":"ytd","weight":-0.0709}],"compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0178},{"period":"3month","weight":0.0085},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2402},{"period":"ytd","weight":0.0463}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}